找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪(fǎng)問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Neuroendocrine Neoplasia Management; New Approaches for D Giordano Beretta,Alfredo Berruti,Orlando Goletti Book 2021 Springer Nature Switze

[復(fù)制鏈接]
樓主: Adams
21#
發(fā)表于 2025-3-25 04:23:09 | 只看該作者
New Concepts in Pathologyct of the tumor cells and their proliferative activity in terms of the number of mitoses or proliferation index (Ki-67)..In PanNENs, for example, Ki-67 labeling index correlates significantly with overall survival and also with disease progression in patients with advanced neoplasms and with tumor r
22#
發(fā)表于 2025-3-25 11:14:05 | 只看該作者
23#
發(fā)表于 2025-3-25 12:34:34 | 只看該作者
24#
發(fā)表于 2025-3-25 19:25:08 | 只看該作者
25#
發(fā)表于 2025-3-25 23:53:31 | 只看該作者
New Approaches in Medical Therapiesnhibitors (pazopanib, cabozantinib, lenvatinib, axitinib, surufatinib). Moreover, immune checkpoint inhibitors have also been investigated in NETs, with some encouraging results in well-differentiated tumors, especially for lung NETs. Clinical studies have also investigated the efficacy of epigeneti
26#
發(fā)表于 2025-3-26 02:36:37 | 只看該作者
Locoregional Therapies of NEN On the other hand, liver ablation, firstly introduced for percutaneous imaging-guided approach and more recently also applied in open and laparoscopic setting, can provide eradication of liver metastases with less invasiveness than traditional surgery. Moreover, due to the high rate of relapse afte
27#
發(fā)表于 2025-3-26 07:17:32 | 只看該作者
NETs of the Lungin receptors (SSTRs). Systemic chemotherapy is reserved for those cases of locally advanced or metastatic disease, even if the standard regimen has not yet been defined. The role of targeted therapies in LCs remains still limited with the exception of the only approved drug (everolimus) in clinical
28#
發(fā)表于 2025-3-26 11:13:44 | 只看該作者
29#
發(fā)表于 2025-3-26 13:38:54 | 只看該作者
Treatment of Pancreatic Neuroendocrine TumorsRRT) are all adequately supported by strong scientific data, and there are no clear criteria that favor the choice of one treatment over the other. The decision-making process should be conducted as part of a multidisciplinary tumor board and must be based on some key elements: the Grade (G 1,2,3),
30#
發(fā)表于 2025-3-26 19:44:08 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 06:10
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
文安县| 克什克腾旗| 通许县| 华宁县| 九江县| 麻栗坡县| 苗栗市| 兴国县| 齐齐哈尔市| 高密市| 锦州市| 东乌珠穆沁旗| 西峡县| 惠东县| 都昌县| 博白县| 邳州市| 玉树县| 南乐县| 额敏县| 乐平市| 甘肃省| 滁州市| 宁远县| 金平| 邳州市| 梁山县| 岑巩县| 天水市| 滨州市| 汉源县| 哈巴河县| 隆回县| 凤山市| 绥阳县| 澎湖县| 正宁县| 乌拉特中旗| 苍梧县| 永川市| 色达县|